Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Conditions:   Recurrent Squamous Cell Carcinoma of the Head or Neck;   Platinum- and Cetuximab-Refractory Squamous Cell Carcinoma of the Head or Neck;   Metastatic Squamous Cell Carcinoma of the Head or Neck;   Squamous Cell Carcinoma
Interventions:   Drug: Nivolumab;   Drug: Afatinib
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Comprehensive Cancer Network;   Boehringer Ingelheim
Not yet recruiting

https://ift.tt/2NvXn6D